

FILE 'MEDLINE' ENTERED AT 20:36:57 ON 24 MAY 2007

FILE 'BIOSIS' ENTERED AT 20:36:57 ON 24 MAY 2007

Copyright (c) 2007 The Thomson Corporation

=> s metal and crosslinking
L1 268 METAL AND CROSSLINKING

=> s l1 and redo
L2 0 L1 AND REDO

=> s l1 and redox
L3 6 L1 AND REDOX

=> s l1 and Alzheimer
L4 3 L1 AND ALZHEIMER

=> s l3 and l4
L5 0 L3 AND L4

=> s l1 and l4
L6 3 L1 AND L4

=> s l1 and alzheimer
L7 3 L1 AND ALZHEIMER

=> dup rem 17
PROCESSING COMPLETED FOR L7
L8 2 DUP REM L7 (1 DUPLICATE REMOVED)

=> disp 18 ibib abs 1-2

L8 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2000318321 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10860544
TITLE: Metal-catalyzed oxidation of alpha-synuclein in
the presence of Copper(II) and hydrogen peroxide.
AUTHOR: Paik S R; Shin H J; Lee J H
CORPORATE SOURCE: Department of Biochemistry, College of Medicine, Inha
University, 253 Yonghyun-Dong, Inchon, 402-751, Korea..
sraik@dragon.inha.ac.kr
SOURCE: Archives of biochemistry and biophysics, (2000 Jun 15) Vol.
378, No. 2, pp. 269-77.
Journal code: 0372430. ISSN: 0003-9861.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200007
ENTRY DATE: Entered STN: 28 Jul 2000
Last Updated on STN: 28 Jul 2000
Entered Medline: 17 Jul 2000
AB alpha-Synuclein is a component of abnormal protein depositions of Lewy
bodies and senile plaques found in Parkinson's and Alzheimer's
diseases, respectively. By using chemical coupling reagents such as
dicyclohexylcarbodiimide or N-(ethoxycarbonyl)-2-ethoxy-1,
2-dihydroquinoline, the protein was shown to experience
self-oligomerization in the presence of either copper(II) or Abeta25-35.
The oligomers which appeared as a ladder on a 10-20% Tricine/SDS-PAGE have
been suggested to participate in the formation of protein aggregations by
possibly providing a nucleation center. Since oxidatively modified
protein could increase its own tendency toward protein aggregation,

Case # 10/643226

STN (BIOSIS, MEDLINE)

AD

5/24/07

metal-catalyzed oxidation of alpha-synuclein has been examined with copper(II) and hydrogen peroxide in the absence of the coupling reagent. Intriguingly, the protein was also self-oligomerized into an SDS-resistant ladder on the gel. This biochemically specific copper-mediated oxidative oligomerization was shown to be dependent upon the acidic C-terminus of alpha-synuclein because the C-terminally truncated proteins such as alpha-syn114 and alpha-syn97 were not affected by the metal and hydrogen peroxide. More importantly, the oxidative oligomerization was synergistically enhanced by the presence of Abeta25-35, indicating that the peptide interaction with alpha-synuclein facilitated the copper(II) binding to the acidic C-terminus and subsequent oxidative crosslinking. It has been, therefore, suggested that abnormalities in copper and H₂O₂ homeostasis and certain pathological factors functionally similar to the Abeta25-35 could play critical roles in the metal-catalyzed oxidative oligomerization of alpha-synuclein, which may lead to possible protein aggregation and neurodegenerations.

Copyright 2000 Academic Press.

L8 ANSWER 2 OF 2 MEDLINE on STN
ACCESSION NUMBER: 97217628 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9063589
TITLE: Advanced glycation endproducts in ageing and Alzheimer's disease.
AUTHOR: Munch G; Thome J; Foley P; Schinzel R; Riederer P
CORPORATE SOURCE: Physiological Chemistry I, Theodor-Boveri-Institut (Biozentrum), Wurzburg, Germany.. muench@biozentrum.uni-wuerzburg.de
SOURCE: Brain research. Brain research reviews, (1997 Feb) Vol. 23, No. 1-2, pp. 134-43. Ref: 78
Journal code: 8908638. ISSN: 0165-0173.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199705
ENTRY DATE: Entered STN: 9 Jun 1997
Last Updated on STN: 6 Feb 1998
Entered Medline: 23 May 1997
AB Accumulation of advanced glycation endproducts (AGE) in the brain is a feature of ageing and degeneration, especially in Alzheimer's disease (AD). Increased AGE levels explain many of the neuropathological and biochemical features of AD such as extensive protein crosslinking (beta-amyloid and MAP-tau), oxidative stress and neuronal cell death. Oxidative stress and AGEs initiate a positive feedback loop, where normal age-related changes develop into a pathophysiological cascade. Combined intervention using antioxidants, metal chelators, anti-inflammatory drugs and AGE-inhibitors may be a promising neuroprotective strategy.

=>

FILE 'CAPLUS' ENTERED AT 20:44:19 ON 24 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 May 2007 VOL 146 ISS 22
FILE LAST UPDATED: 23 May 2007 (20070523/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> E BUSH ASHLEY I/IN 25
E1 1 BUSH ARTHUR B JR/IN
E2 1 BUSH ASHLEY/IN
E3 10 --> BUSH ASHLEY I/IN
E4 3 BUSH ASHLEY IAN/IN
E5 1 BUSH ASHLEY L/IN
E6 1 BUSH BRADLEY S/IN
E7 1 BUSH BRADLEY STEPHEN/IN
E8 1 BUSH BRIAN/IN
E9 2 BUSH BRIAN DAVID/IN
E10 1 BUSH C ALLEN/IN
E11 1 BUSH CAROL L/IN
E12 1 BUSH CAROLE/IN
E13 1 BUSH CATHERINE/IN
E14 1 BUSH CHARLENE ELEANOR/IN
E15 1 BUSH CHARLES HUNTER/IN
E16 8 BUSH CHARLES N/IN
E17 2 BUSH CHARLES NEAL/IN
E18 1 BUSH CHRISTOPHER/IN
E19 2 BUSH CHRISTOPHER DAVID/IN
E20 1 BUSH CHRISTOPHER JOHN THOMSON/IN
E21 1 BUSH CHRISTOPHER N/IN
E22 3 BUSH CONDON S/IN
E23 1 BUSH CRAIG P/IN
E24 2 BUSH CRAIG PALMER/IN
E25 1 BUSH DARRELL/IN

=> S (E3) AND (METAL, CROSSLINKING, REDOX)
10 "BUSH ASHLEY I"/IN
1738022 METAL
875848 METALS
2109471 METAL
(METAL OR METALS)
201885 CROSSLINKING
134 CROSSLINKINGS
201944 CROSSLINKING
(CROSSLINKING OR CROSSLINKINGS)
137447 REDOX
8 REDOXES

137450 REDOX
 (REDOX OR REDOXES)
 0 METAL, CROSSLINKING, REDOX
 (METAL (W) CROSSLINKING (W) REDOX)
L1 0 ("BUSH ASHLEY I"/IN) AND (METAL, CROSSLINKING, REDOX)

=> S (E3) AND (METAL, CROSSLINKING)
 10 "BUSH ASHLEY I"/IN
1738022 METAL
875848 METALS
2109471 METAL
 (METAL OR METALS)
201885 CROSSLINKING
134 CROSSLINKINGS
201944 CROSSLINKING
 (CROSSLINKING OR CROSSLINKINGS)
154 METAL, CROSSLINKING
 (METAL (W) CROSSLINKING)
L2 0 ("BUSH ASHLEY I"/IN) AND (METAL, CROSSLINKING)

=> S (E3) AND (CROSSLINKING, ALZHEIMER)
 10 "BUSH ASHLEY I"/IN
201885 CROSSLINKING
134 CROSSLINKINGS
201944 CROSSLINKING
 (CROSSLINKING OR CROSSLINKINGS)
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
7 CROSSLINKING, ALZHEIMER
 (CROSSLINKING (W) ALZHEIMER)
L3 0 ("BUSH ASHLEY I"/IN) AND (CROSSLINKING, ALZHEIMER)

=> S (E3) AND (ALZHEIMER)
 10 "BUSH ASHLEY I"/IN
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
L4 7 ("BUSH ASHLEY I"/IN) AND (ALZHEIMER)

=> S (E3) AND (ALZHEIMER, METAL)
 10 "BUSH ASHLEY I"/IN
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
1738022 METAL
875848 METALS
2109471 METAL
 (METAL OR METALS)
1 ALZHEIMER, METAL
 (ALZHEIMER (W) METAL)
L5 0 ("BUSH ASHLEY I"/IN) AND (ALZHEIMER, METAL)

=> S (E3) AND (ALZHEIMER)
 10 "BUSH ASHLEY I"/IN
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
L6 7 ("BUSH ASHLEY I"/IN) AND (ALZHEIMER)

=> DIS L6 1 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:453721 CAPLUS
DOCUMENT NUMBER: 142:476270
TITLE: Method of screening for drugs useful in treating Alzheimer's disease based on alteration of production of reduced metal ions and hydrogen peroxide
INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 380,704.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005112543	A1	20050526	US 2003-643226	20030819
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6638711	B1	20031028	US 2000-560883	20000428
US 7045531	B1	20060516	US 2000-380704	20000606
PRIORITY APPLN. INFO.:			WO 1998-US4683	W 19980311
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606
			US 1997-816122	A2 19970311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908

ABSTRACT:

The invention discloses methods for identifying candidate pharmacol. agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathol. conditions. The methodol. of the invention involves determining whether the agent is capable of altering production of hydrogen peroxide, Cu(I), or Fe(II).

=> DIS L6 2 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:851242 CAPLUS
DOCUMENT NUMBER: 139:333141
TITLE: Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.

PATENT ASSIGNEE(S) : The General Hospital Corporation, USA
 SOURCE: U.S., 48 pp., Cont.-in-part of U.S. Ser. No. 380,704.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6638711	B1	20031028	US 2000-560883	20000428
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2005112543	A1	20050526	US 2003-643226	20030819
PRIORITY APPLN. INFO.:				
			US 1997-816122	A 19970311
			WO 1998-US4683	W 19980311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606

ABSTRACT:

The present invention is directed to the identification of agents that can be used to decrease the neurotoxicity of amyloid β ($A\beta$) and the formation of $A\beta$ polymers, and to the use of such agents to develop methods of preventing, treating or alleviating Alzheimer's disease (AD) and/or the symptoms of AD. More specifically, the present invention is directed to the identification of agents that could be used to treat AD. Because the ability of $A\beta$ to function as an antioxidant, i.e., to generate H_2O_2 from O_2^- may, in many instances, be beneficial, the invention also relates to a method for identifying an agent to be used in the treatment and/or prevention of AD and symptoms thereof, wherein said agent is capable of interfering with the interaction of O_2 and $A\beta$ to generate H_2O_2 without interfering with the SOD-like activity of $A\beta$, i.e., the ability of $A\beta$ to function as an antioxidant. Thus, the invention relates to a method for the identification of an agent to be used in the treatment and/or prevention of AD and/or symptoms thereof, wherein the agent inhibits oxygen-dependent hydrogen peroxide formation activity, but does not inhibit the superoxide-dependent hydrogen peroxide formation, the method comprising: (a) adding the agent to an $A\beta$ -containing sample; (b) determining whether the agent is capable of inhibiting dissolved oxygen-dependent hydrogen peroxide formation; and (c) determining whether the agent is capable of not inhibiting the $A\beta$ -catalyzed superoxide-dependent hydrogen peroxide formation. In a preferred embodiment, the method of determining whether the agent is capable of not inhibiting the superoxide-dependent hydrogen peroxide formation is conducted using pulse radiolysis or the NBT assay. In a preferred embodiment, the determination of the ability of the agent to inhibit the $A\beta$ -catalyzed superoxide-dependent hydrogen peroxide formation is made by determining whether $A\beta$ is capable of catalytically producing Cu(I), Fe(II) or H_2O_2 .

REFERENCE COUNT: 208 THERE ARE 208 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST	42.18	42.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

FILE 'STNGUIDE' ENTERED AT 20:47:17 ON 24 MAY 2007
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: May 18, 2007 (20070518/UP).

=> FIL CAPLUS		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	42.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.56

FILE 'CAPLUS' ENTERED AT 20:47:55 ON 24 MAY 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 May 2007 VOL 146 ISS 22
 FILE LAST UPDATED: 23 May 2007 (20070523/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
 They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> DIS L6 3 IBIB IABS
 THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:158386 CAPLUS
 DOCUMENT NUMBER: 136:178011
 TITLE: Use of clioquinol for the therapy of Alzheimer
 's disease
 INVENTOR(S): Bush, Ashley I.; Tanzi, Rudolph E.; Xilinas,
 Mikhel; Cherny, Robert
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont. of U.S. Ser. No.
 560,887.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002025944	A1	20020228	US 2001-972913	20011010
US 2006074104	A1	20060406	US 2005-99693	20050406
PRIORITY APPLN. INFO.:			US 1998-32777	A 19980306
			US 2000-560887	A1 20000428
			US 1999-224953	B1 19990104
			US 2001-972913	A1 20011010

ABSTRACT:

The invention relates to the identification of clioquinol as a pharmaceutically therapeutic agent for treatment of Alzheimer's disease and related pathol. conditions. Very low doses (8 nM) of clioquinol resolubilized more than twice the amount of β -amyloid compared to PBS alone.

=> DIS L6 4 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:790364 CAPLUS
DOCUMENT NUMBER: 133:344631
TITLE: Method of screening for drugs useful in treating
Alzheimer's disease
INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood,
Craig S.; Tanzi, Rudolph E.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066181	A1	20001109	WO 2000-US11715	20000501
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371768	A1	20001109	CA 2000-2371768	20000501
EP 1196198	A1	20020417	EP 2000-928644	20000501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543402	T	20021217	JP 2000-615064	20000501
AU 776951	B2	20040930	AU 2000-46849	20000501
PRIORITY APPLN. INFO.:			US 1999-131579P	P 19990429
			WO 2000-US11715	W 20000501

ABSTRACT:

Methods are provided for identifying candidate pharmacol. agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathol. conditions.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 5 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:621114 CAPLUS
DOCUMENT NUMBER: 129:239902
TITLE: Identification of agents for use in the treatment of Alzheimer's disease, and methods and compositions for treatment of conditions caused by amyloidosis and/or A β -mediated ROS formation
INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
PATENT ASSIGNEE(S): The General Hospital Corp., USA
SOURCE: PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2284170	A1	19980917	CA 1998-2284170	19980311
AU 9865484	A	19980929	AU 1998-65484	19980311
AU 748768	B2	20020613		
EP 1007048	A1	20000614	EP 1998-911551	19980311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514661	T	20010911	JP 1998-539718	19980311
US 6638711	B1	20031028	US 2000-560883	20000428
US 7045531	B1	20060516	US 2000-380704	20000606
AU 2002301084	A1	20030227	AU 2002-301084	20020912
US 2005112543	A1	20050526	US 2003-643226	20030819
PRIORITY APPLN. INFO.:			US 1997-816122	A2 19970311
			AU 1998-65484	A3 19980311
			WO 1998-US4683	W 19980311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606

ABSTRACT:

The invention relates to the identification of pharmacol. agents to be used in the treatment of Alzheimer's disease and related pathol. conditions. Methods and compns. for treatment of conditions caused by amyloidosis, A β -mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 6 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:397325 CAPLUS
DOCUMENT NUMBER: 125:53039
TITLE: A diagnostic assay for Alzheimer's disease:
assessment of a beta abnormalities
INVENTOR(S): Tanzi, Rudolph E.; Bush, Ashley I.; Moir,
Robert D.
PATENT ASSIGNEE(S): General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9612544	A1	19960502	WO 1994-US11895	19941019
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2203142	A1	19960502	CA 1994-2203142	19941019
CA 2203142	C	20060131		
AU 9480830	A	19960515	AU 1994-80830	19941019
US 5972634	A	19991026	US 1997-817423	19970804
US 2003073074	A1	20030417	US 1999-425956	19991025
US 6890727	B2	20050510		
PRIORITY APPLN. INFO.:			WO 1994-US11895	A 19941019
			US 1997-817423	A1 19970804

ABSTRACT:

The disclosed invention relates to assays for detecting and quantifying $\alpha\beta$ peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of $\text{A}\beta$ peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of $\text{A}\beta$ peptides from biol. fluids are taught.

=> DIS L6 7 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:340771 CAPLUS
DOCUMENT NUMBER: 125:7574
TITLE: An in vitro system for determining formation of a beta amyloid
INVENTOR(S): Tanzi, Rudolph E.; Bush, Ashley I.
PATENT ASSIGNEE(S): General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9607096	A1	19960307	WO 1994-US11928	19941019
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6365414	B1	20020402	US 1994-294819	19940826
CA 2205085	A1	19960307	CA 1994-2205085	19941019
AU 9481223	A	19960322	AU 1994-81223	19941019
JP 10509510	T	19980914	JP 1996-508706	19941019
JP 3459069	B2	20031020		
US 2002115223	A1	20020822	US 2002-41605	20020110
JP 2004061494	A	20040226	JP 2003-145592	20030523
PRIORITY APPLN. INFO.:				
			US 1994-294819	A 19940826
			JP 1994-508706	A3 19941019
			WO 1994-US11928	W 19941019

ABSTRACT:

The invention relates to rapid methods for determining formation of A β amyloid and screening compds. which inhibit formation of A β amyloid in vitro, as well as kits for carrying out the present methods. Such an agent used in vivo may prevent, ameliorate or reverse the symptoms of Alzheimer's disease and A β amyloidotic disorders related to Alzheimer's disease and Down's syndrome. The process described in this invention involves the rapid induction of A β amyloid by a heavy metal cation capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A β , such as zinc to form amyloid and determination of formation of tinctorial A β amyloid.

=> E HUANG XUDONG/IN 25

E1 1 HUANG XUANYI/IN
E2 1 HUANG XUBIN/IN
E3 17 --> HUANG XUDONG/IN
E4 3 HUANG XUE F/IN
E5 1 HUANG XUE LIN/IN
E6 2 HUANG XUEBIN/IN
E7 4 HUANG XUECHAO/IN
E8 2 HUANG XUEFEI/IN
E9 1 HUANG XUEFEN/IN
E10 1 HUANG XUEFENG/IN
E11 3 HUANG XUEHONG/IN
E12 1 HUANG XUEHUA/IN
E13 5 HUANG XUEHUI/IN
E14 34 HUANG XUEJIE/IN
E15 1 HUANG XUEJIN/IN
E16 1 HUANG XUEJING/IN
E17 1 HUANG XUEJU/IN
E18 1 HUANG XUEJUE/IN
E19 1 HUANG XUEJUN/IN
E20 1 HUANG XUELIAO/IN
E21 2 HUANG XUELUN/IN
E22 3 HUANG XUEMEI/IN
E23 3 HUANG XUEMIN/IN
E24 1 HUANG XUENAN/IN
E25 1 HUANG XUENGUANG/IN

=> S (E3) AND (ALZHEIMER)
17 "HUANG XUDONG"/IN
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
(ALZHEIMER OR ALZHEIMERS)
L7 7 ("HUANG XUDONG"/IN) AND (ALZHEIMER)

=> DIS L7 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:149001 CAPLUS
DOCUMENT NUMBER: 144:219303
TITLE: Amyloid-binding, metal-chelating agents
INVENTOR(S): Huang, Xudong; Kremsky, Jonathan L.;
Catchings, Perry L.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA; Prime Organics,
Inc.
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S.
Ser. No. 762,965.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006035946	A1	20060216	US 2005-96919	20050401
US 2004204344	A1	20041014	US 2004-762965	20040122
PRIORITY APPLN. INFO.:			US 2003-441719P	P 20030122
			US 2004-762965	A2 20040122

OTHER SOURCE(S): MARPAT 144:219303

ABSTRACT:

The present invention relates to the diagnosis, prevention, and treatment of pathophysiol. conditions associated with amyloid accumulation. Bifunctional therapeutic mols. and contrast imaging agents exhibiting a high affinity for amyloid deposits, and pharmaceutical compns. thereof are described. The invention also provides methods of using these bifunctional mols., contrast imaging agents, and pharmaceutical compns. for detecting the presence of amyloid deposits using imaging techniques; and for preventing or treating amyloid-related conditions, such as, for example, Alzheimer's disease.

=> DIS L7 2 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:453721 CAPLUS
DOCUMENT NUMBER: 142:476270
TITLE: Method of screening for drugs useful in treating
Alzheimer's disease based on alteration of
production of reduced metal ions and hydrogen peroxide
INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood,
Craig S.; Tanzi, Rudolph E.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S.
Ser. No. 380,704.
CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005112543	A1	20050526	US 2003-643226	20030819
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6638711	B1	20031028	US 2000-560883	20000428
US 7045531	B1	20060516	US 2000-380704	20000606
PRIORITY APPLN. INFO.:				
			WO 1998-US4683	W 19980311
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606
			US 1997-816122	A2 19970311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908

ABSTRACT:

The invention discloses methods for identifying candidate pharmacol. agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathol. conditions. The methodol. of the invention involves determining whether the agent is capable of altering production of hydrogen peroxide, Cu(I), or Fe(II).

=> DIS L7 3 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:633552 CAPLUS
 DOCUMENT NUMBER: 141:179563
 TITLE: Amyloid-binding, metal-chelating imaging and therapeutic agents
 INVENTOR(S): Huang, Xudong
 PATENT ASSIGNEE(S): The General Hospital Corporation, USA
 SOURCE: PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064869	A2	20040805	WO 2004-US1669	20040122
WO 2004064869	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004206956	A1	20040805	AU 2004-206956	20040122
CA 2514200	A1	20040805	CA 2004-2514200	20040122
EP 1587547	A2	20051026	EP 2004-704402	20040122

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1774267 A 20060517 CN 2004-80004902 20040122
 JP 2006515630 T 20060601 JP 2006-501093 20040122
 IN 2005KN01662 A 20060922 IN 2005-KN1662 20050819
 PRIORITY APPLN. INFO.: US 2003-441719P P 20030122
 WO 2004-US1669 W 20040122

OTHER SOURCE(S) : MARPAT 141:179563

ABSTRACT:

The present invention relates to the diagnosis, prevention, and treatment of pathophysiol. conditions associated with amyloid accumulation. Bifunctional therapeutic mols. and contrast imaging agents exhibiting a high affinity for amyloid deposits, and pharmaceutical compns. thereof are described. The invention also provides methods of using these bifunctional mols., contrast imaging agents, and pharmaceutical compns. for detecting the presence of amyloid deposits using imaging techniques; and for preventing or treating amyloid-related conditions, such as, for example, Alzheimer's disease.

=> DIS L7 4 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:851242 CAPLUS

DOCUMENT NUMBER: 139:333141

TITLE: Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation

INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.

PATENT ASSIGNEE(S): The General Hospital Corporation, USA

SOURCE: U.S., 48 pp., Cont.-in-part of U.S. Ser. No. 380,704.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6638711	B1	20031028	US 2000-560883	20000428
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2005112543	A1	20050526	US 2003-643226	20030819
PRIORITY APPLN. INFO.:			US 1997-816122	A 19970311
			WO 1998-US4683	W 19980311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606

ABSTRACT:

The present invention is directed to the identification of agents that can be used to decrease the neurotoxicity of amyloid β ($A\beta$) and the

formation of A β polymers, and to the use of such agents to develop methods of preventing, treating or alleviating Alzheimer's disease (AD) and/or the symptoms of AD. More specifically, the present invention is directed to the identification of agents that could be used to treat AD. Because the ability of A β to function as an antioxidant, i.e., to generate H₂O₂ from O₂⁻ may, in many instances, be beneficial, the invention also relates to a method for identifying an agent to be used in the treatment and/or prevention of AD and symptoms thereof, wherein said agent is capable of interfering with the interaction of O₂ and A β to generate H₂O₂ without interfering with the SOD-like activity of A β , i.e., the ability of A β to function as an antioxidant. Thus, the invention relates to a method for the identification of an agent to be used in the treatment and/or prevention of AD and/or symptoms thereof, wherein the agent inhibits oxygen-dependent hydrogen peroxide formation activity, but does not inhibit the superoxide-dependent hydrogen peroxide formation, the method comprising: (a) adding the agent to an A β -containing sample; (b) determining whether the agent is capable of inhibiting dissolved oxygen-dependent hydrogen peroxide formation; and (c) determining whether the agent is capable of not inhibiting the A β -catalyzed superoxide-dependent hydrogen peroxide formation. In a preferred embodiment, the method of determining whether the agent is capable of not inhibiting the superoxide-dependent hydrogen peroxide formation is conducted using pulse radiolysis or the NBT assay. In a preferred embodiment, the determination of the ability of the agent to inhibit the A β -catalyzed superoxide-dependent hydrogen peroxide formation is made by determining whether A β is capable of catalytically producing Cu(I), Fe(II) or H₂O₂.

REFERENCE COUNT: 208 THERE ARE 208 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L7 5 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:790364 CAPLUS
DOCUMENT NUMBER: 133:344631
TITLE: Method of screening for drugs useful in treating Alzheimer's disease
INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066181	A1	20001109	WO 2000-US11715	20000501
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371768	A1	20001109	CA 2000-2371768	20000501
EP 1196198	A1	20020417	EP 2000-928644	20000501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO				
JP 2002543402	T 20021217	JP 2000-615064	20000501	
AU 776951	B2 20040930	AU 2000-46849	20000501	
PRIORITY APPLN. INFO.:		US 1999-131579P	P 19990429	
		WO 2000-US11715	W 20000501	

ABSTRACT:

Methods are provided for identifying candidate pharmacol. agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathol. conditions.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L7 6 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:594906 CAPLUS

DOCUMENT NUMBER: 131:209140

TITLE: Agents for use in the treatment of Alzheimer
's disease

INVENTOR(S): Bush, Ashley L.; Huang, Xudong; Atwood,
Craig S.; Tanzi, Rudolph E.

PATENT ASSIGNEE(S): The General Hospital Corporation, USA

SOURCE: PCT Int. Appl., 180 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945907	A2	19990916	WO 1999-US5291	19990311
WO 9945907	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6323218	B1	20011127	US 1998-38154	19980311
CA 2323458	A1	19990916	CA 1999-2323458	19990311
AU 9929981	A	19990927	AU 1999-29981	19990311
AU 752236	B2	20020912		
EP 1061923	A2	20001227	EP 1999-911307	19990311
EP 1061923	B1	20050615		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506020	T	20020226	JP 2000-535322	19990311
AT 297731	T	20050715	AT 1999-911307	19990311
HK 1033907	A1	20051111	HK 2001-104461	20010627
US 2002082273	A1	20020627	US 2001-956980	20010921
AU 2002318888	A1	20030410	AU 2002-318888	20021213
PRIORITY APPLN. INFO.:			US 1998-38154	A 19980311
			AU 1999-29981	A3 19990311
			WO 1999-US5291	W 19990311

ABSTRACT:

The invention relates to the identification of pharmacol. agents to be used in the treatment of Alzheimer's disease and related pathol. conditions

and compns. for treatment of conditions caused by amyloidosis, A β -mediated formation of reactive oxygen species, or both, such as Alzheimer's disease, are disclosed. Examples are given of effects of chelators on extraction or resolubilization of A β . Accumulation of A β in the brain cortex is closely related to the cause of Alzheimer's disease and Cu and Zn are thought to be involved in plaque pathol. Examples of chelators are TPEN, EGTA, TPEN, bathocuproine, and bathophenanthroline.

=> DIS L7 7 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:621114 CAPLUS
 DOCUMENT NUMBER: 129:239902
 TITLE: Identification of agents for use in the treatment of Alzheimer's disease, and methods and compositions for treatment of conditions caused by amyloidosis and/or A β -mediated ROS formation
 INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
 PATENT ASSIGNEE(S): The General Hospital Corp., USA
 SOURCE: PCT Int. Appl., 198 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2284170	A1	19980917	CA 1998-2284170	19980311
AU 9865484	A	19980929	AU 1998-65484	19980311
AU 748768	B2	20020613		
EP 1007048	A1	20000614	EP 1998-911551	19980311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514661	T	20010911	JP 1998-539718	19980311
US 6638711	B1	20031028	US 2000-560883	20000428
US 7045531	B1	20060516	US 2000-380704	20000606
AU 2002301084	A1	20030227	AU 2002-301084	20020912
US 2005112543	A1	20050526	US 2003-643226	20030819
PRIORITY APPLN. INFO.:			US 1997-816122	A2 19970311
			AU 1998-65484	A3 19980311
			WO 1998-US4683	W 19980311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606

ABSTRACT:

The invention relates to the identification of pharmacol. agents to be used in the treatment of Alzheimer's disease and related pathol. conditions. Methods and compns. for treatment of conditions caused by amyloidosis,

$\text{A}\beta$ -mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E ATWOOD CRAIG S/IN 25

E1 2 ATWOOD BRYAN/IN
E2 1 ATWOOD CHARLES T/IN
E3 5 --> ATWOOD CRAIG S/IN
E4 2 ATWOOD DAN/IN
E5 2 ATWOOD DAVID A/IN
E6 3 ATWOOD DAVID ALLAN/IN
E7 3 ATWOOD DONALD K/IN
E8 1 ATWOOD E H/IN
E9 1 ATWOOD EDWARD N/IN
E10 2 ATWOOD EDWARDS S/IN
E11 3 ATWOOD EDWIN H/IN
E12 2 ATWOOD ELBRIDGE L/IN
E13 3 ATWOOD EUGENE R/IN
E14 3 ATWOOD F C/IN
E15 31 ATWOOD FRANCIS C/IN
E16 3 ATWOOD FRANCIS CLARKE/IN
E17 7 ATWOOD GEO E/IN
E18 7 ATWOOD GEORGE E/IN
E19 3 ATWOOD GEORGE F/IN
E20 3 ATWOOD GILBERT R/IN
E21 7 ATWOOD GILBERT RICHARD/IN
E22 2 ATWOOD GLENN A/IN
E23 4 ATWOOD GREG/IN
E24 1 ATWOOD GREGORY/IN
E25 3 ATWOOD GREGORY E/IN

=> S (E3) AND (ALZHEIMER)

5 "ATWOOD CRAIG S"/IN
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
(ALZHEIMER OR ALZHEIMERS)
L8 5 ("ATWOOD CRAIG S"/IN) AND (ALZHEIMER)

=> DIS L8 1 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:453721 CAPLUS

DOCUMENT NUMBER: 142:476270

TITLE: Method of screening for drugs useful in treating
Alzheimer's disease based on alteration of
production of reduced metal ions and hydrogen peroxide
Bush, Ashley I.; Huang, Xudong; Atwood, Craig
S.; Tanzi, Rudolph E.

INVENTOR(S):
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S.
Ser. No. 380,704.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2005112543	A1	20050526	US 2003-643226	20030819
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6638711	B1	20031028	US 2000-560883	20000428
US 7045531	B1	20060516	US 2000-380704	20000606
PRIORITY APPLN. INFO.:			WO 1998-US4683	W 19980311
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606
			US 1997-816122	A2 19970311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908

ABSTRACT:

The invention discloses methods for identifying candidate pharmacol. agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathol. conditions. The methodol. of the invention involves determining whether the agent is capable of altering production of hydrogen peroxide, Cu(I), or Fe(II).

=> DIS L8 2 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:851242 CAPLUS
 DOCUMENT NUMBER: 139:333141
 TITLE: Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
 INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
 PATENT ASSIGNEE(S): The General Hospital Corporation, USA
 SOURCE: U.S., 48 pp., Cont.-in-part of U.S. Ser. No. 380,704.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6638711	B1	20031028	US 2000-560883	20000428
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2005112543	A1	20050526	US 2003-643226	20030819
PRIORITY APPLN. INFO.:			US 1997-816122	A 19970311

WO 1998-US4683	W 19980311
US 1999-131579P	P 19990429
US 1999-380704	A2 19990908
US 2000-560883	A3 20000428
US 2000-380704	A2 20000606

ABSTRACT:

The present invention is directed to the identification of agents that can be used to decrease the neurotoxicity of amyloid β ($A\beta$) and the formation of $A\beta$ polymers, and to the use of such agents to develop methods of preventing, treating or alleviating Alzheimer's disease (AD) and/or the symptoms of AD. More specifically, the present invention is directed to the identification of agents that could be used to treat AD. Because the ability of $A\beta$ to function as an antioxidant, i.e., to generate H_2O_2 from O_2^- may, in many instances, be beneficial, the invention also relates to a method for identifying an agent to be used in the treatment and/or prevention of AD and symptoms thereof, wherein said agent is capable of interfering with the interaction of O_2 and $A\beta$ to generate H_2O_2 without interfering with the SOD-like activity of $A\beta$, i.e., the ability of $A\beta$ to function as an antioxidant. Thus, the invention relates to a method for the identification of an agent to be used in the treatment and/or prevention of AD and/or symptoms thereof, wherein the agent inhibits oxygen-dependent hydrogen peroxide formation activity, but does not inhibit the superoxide-dependent hydrogen peroxide formation, the method comprising: (a) adding the agent to an $A\beta$ -containing sample; (b) determining whether the agent is capable of inhibiting dissolved oxygen-dependent hydrogen peroxide formation; and (c) determining whether the agent is capable of not inhibiting the $A\beta$ -catalyzed superoxide-dependent hydrogen peroxide formation. In a preferred embodiment, the method of determining whether the agent is capable of not inhibiting the superoxide-dependent hydrogen peroxide formation is conducted using pulse radiolysis or the NBT assay. In a preferred embodiment, the determination of the ability of the agent to inhibit the $A\beta$ -catalyzed superoxide-dependent hydrogen peroxide formation is made by determining whether $A\beta$ is capable of catalytically producing Cu(I), Fe(II) or H_2O_2 .

REFERENCE COUNT: 208 **THERE ARE 208 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT**

=> DIS L8 3 IBIB IABS
 THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:790364 CAPLUS
 DOCUMENT NUMBER: 133:344631
 TITLE: Method of screening for drugs useful in treating Alzheimer's disease
 INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
 PATENT ASSIGNEE(S): The General Hospital Corporation, USA
 SOURCE: PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066181	A1	20001109	WO 2000-US11715	20000501
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				

LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2371768 A1 20001109 CA 2000-2371768 20000501
 EP 1196198 A1 20020417 EP 2000-928644 20000501
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002543402 T 20021217 JP 2000-615064 20000501
 AU 776951 B2 20040930 AU 2000-46849 20000501
 PRIORITY APPLN. INFO.: US 1999-131579P P 19990429
 WO 2000-US11715 W 20000501

ABSTRACT:

Methods are provided for identifying candidate pharmacol. agents to be used in the treatment and/or prevention of Alzheimer's disease and/or related pathol. conditions.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L8 4 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:594906 CAPLUS
 DOCUMENT NUMBER: 131:209140
 TITLE: Agents for use in the treatment of Alzheimer
 's disease
 INVENTOR(S): Bush, Ashley L.; Huang, Xudong; Atwood, Craig
 S.; Tanzi, Rudolph E.
 PATENT ASSIGNEE(S): The General Hospital Corporation, USA
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945907	A2	19990916	WO 1999-US5291	19990311
WO 9945907	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6323218	B1	20011127	US 1998-38154	19980311
CA 2323458	A1	19990916	CA 1999-2323458	19990311
AU 9929981	A	19990927	AU 1999-29981	19990311
AU 752236	B2	20020912		
EP 1061923	A2	20001227	EP 1999-911307	19990311
EP 1061923	B1	20050615		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506020	T	20020226	JP 2000-535322	19990311
AT 297731	T	20050715	AT 1999-911307	19990311
HK 1033907	A1	20051111	HK 2001-104461	20010627

US 2002082273	A1	20020627	US 2001-956980	20010921
AU 2002318888	A1	20030410	AU 2002-318888	20021213
PRIORITY APPLN. INFO.:			US 1998-38154	A 19980311
			AU 1999-29981	A3 19990311
			WO 1999-US5291	W 19990311

ABSTRACT:

The invention relates to the identification of pharmacol. agents to be used in the treatment of Alzheimer's disease and related pathol. conditions and compns. for treatment of conditions caused by amyloidosis, A β -mediated formation of reactive oxygen species, or both, such as Alzheimer's disease, are disclosed. Examples are given of effects of chelators on extraction or resolubilization of A β . Accumulation of A β in the brain cortex is closely related to the cause of Alzheimer's disease and Cu and Zn are thought to be involved in plaque pathol. Examples of chelators are TPEN, EGTA, TPEN, bathocuproine, and bathophenanthroline.

=> DIS L8 5 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:621114 CAPLUS
 DOCUMENT NUMBER: 129:239902
 TITLE: Identification of agents for use in the treatment of Alzheimer's disease, and methods and compositions for treatment of conditions caused by amyloidosis and/or A β -mediated ROS formation
 INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
 PATENT ASSIGNEE(S): The General Hospital Corp., USA
 SOURCE: PCT Int. Appl., 198 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2284170	A1	19980917	CA 1998-2284170	19980311
AU 9865484	A	19980929	AU 1998-65484	19980311
AU 748768	B2	20020613		
EP 1007048	A1	20000614	EP 1998-911551	19980311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514661	T	20010911	JP 1998-539718	19980311
US 6638711	B1	20031028	US 2000-560883	20000428
US 7045531	B1	20060516	US 2000-380704	20000606
AU 2002301084	A1	20030227	AU 2002-301084	20020912
US 2005112543	A1	20050526	US 2003-643226	20030819
PRIORITY APPLN. INFO.:			US 1997-816122	A2 19970311
			AU 1998-65484	A3 19980311
			WO 1998-US4683	W 19980311

US 1999-131579P P 19990429
US 1999-380704 A2 19990908
US 2000-560883 A3 20000428
US 2000-380704 A2 20000606

ABSTRACT:

The invention relates to the identification of pharmacol. agents to be used in the treatment of Alzheimer's disease and related pathol. conditions. Methods and compns. for treatment of conditions caused by amyloidosis, A β -mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E TANZI RUDOLPH E/IN 25
E1 1 TANZI MARIO/IN
E2 3 TANZI RUDOLPH/IN
E3 28 --> TANZI RUDOLPH E/IN
E4 1 TANZI STEVEN/IN
E5 1 TANZIAWA TUNEYUKI/IN
E6 2 TANZILLI JAMES D/IN
E7 3 TANZILLI RICHARD A/IN
E8 1 TANZILLI RICHARD ANTHONY/IN
E9 1 TANZINI SAURO/IN
E10 2 TANZLER RICHARD/IN
E11 8 TANZMAN DANIEL P/IN
E12 1 TANZMAN HERBERT D/IN
E13 1 TANZMANN DANIEL/IN
E14 1 TANZMANN LUBOMIR CS/IN
E15 1 TANZMANN WOLFGANG/IN
E16 1 TANZMEIER PETER/IN
E17 4 TANZO ATSUHARU/IN
E18 11 TANZO JUNJI/IN
E19 1 TANZO TOMOHARU/IN
E20 4 TANZO TOMOJI/IN
E21 1 TANZOLA JOHN C/IN
E22 3 TANZOLA WM A/IN
E23 5 TANZOSH JAMES M/IN
E24 7 TANZYBAEVA L V/IN
E25 1 TANZYBAEVA LYUDMILA V/IN

=> S (E3) AND (ALZHEIMER)
28 "TANZI RUDOLPH E"/IN
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
(ALZHEIMER OR ALZHEIMERS)

L9 25 ("TANZI RUDOLPH E"/IN) AND (ALZHEIMER)

=> S (E3) AND (ALZHEIMER, METAL)
28 "TANZI RUDOLPH E"/IN
44955 ALZHEIMER
790 ALZHEIMERS
45017 ALZHEIMER
(ALZHEIMER OR ALZHEIMERS)
1738022 METAL
875848 METALS
2109471 METAL
(METAL OR METALS)
1 ALZHEIMER, METAL
(ALZHEIMER (W) METAL)

L10 0 ("TANZI RUDOLPH E"/IN) AND (ALZHEIMER, METAL)

=> S (E3) AND (ALZHEIMER, CROSS)
 28 "TANZI RUDOLPH E"/IN
 44955 ALZHEIMER
 790 ALZHEIMERS
 45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
 521516 CROSS
 18813 CROSSES
 537688 CROSS
 (CROSS OR CROSSES)
 0 ALZHEIMER, CROSS
 (ALZHEIMER (W) CROSS)
L11 0 ("TANZI RUDOLPH E"/IN) AND (ALZHEIMER, CROSS)

=> S (E3) AND (ALZHEIMER, AGENT)
 28 "TANZI RUDOLPH E"/IN
 44955 ALZHEIMER
 790 ALZHEIMERS
 45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
 844080 AGENT
 1231248 AGENTS
 1728561 AGENT
 (AGENT OR AGENTS)
 67 ALZHEIMER, AGENT
 (ALZHEIMER (W) AGENT)
L12 0 ("TANZI RUDOLPH E"/IN) AND (ALZHEIMER, AGENT)

=> S (E3) AND (ALZHEIMER, PHARMACEUTICAL)
 28 "TANZI RUDOLPH E"/IN
 44955 ALZHEIMER
 790 ALZHEIMERS
 45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
 239450 PHARMACEUTICAL
 89561 PHARMACEUTICALS
 293363 PHARMACEUTICAL
 (PHARMACEUTICAL OR PHARMACEUTICALS)
 0 ALZHEIMER, PHARMACEUTICAL
 (ALZHEIMER (W) PHARMACEUTICAL)
L13 0 ("TANZI RUDOLPH E"/IN) AND (ALZHEIMER, PHARMACEUTICAL)

=> S (E3) AND (ALZHEIMER DISEASE)
 28 "TANZI RUDOLPH E"/IN
 44955 ALZHEIMER
 790 ALZHEIMERS
 45017 ALZHEIMER
 (ALZHEIMER OR ALZHEIMERS)
 956159 DISEASE
 258774 DISEASES
 1071877 DISEASE
 (DISEASE OR DISEASES)
 17796 ALZHEIMER DISEASE
 (ALZHEIMER (W) DISEASE)
L14 17 ("TANZI RUDOLPH E"/IN) AND (ALZHEIMER DISEASE)

=> DIS L14 1 IBIB IABS
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L14 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:698235 CAPLUS
DOCUMENT NUMBER: 143:186773
TITLE: Methods and compositions relating to modulating

INVENTOR(S) : amyloid precursor protein cleavage
 Puglielli, Luigi; Huttunen, Henri J.; Guenette,
 Suzanne Y.; Tanzi, Rudolph E.; Kovacs, Dora
 M.
 PATENT ASSIGNEE(S) : The General Hospital Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 34 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005170437	A1	20050804	US 2004-984017	20041108
PRIORITY APPLN. INFO.:			US 2003-518355P	P 20031107

ABSTRACT:
 The invention relates in part assays for identifying and testing compds. that modulate cleavage of amyloid precursor protein (APP). In addition, the invention relates to novel cleavage products of APP. The invention addnl. relates to methods and assays for identifying compds. that inhibit acyl-CoA:cholesterol acyltransferase (ACAT) activity. The methods and products of the invention are useful for identifying compds. to prevent and/or treat APP-cleavage associated disorders (e.g. Alzheimer's disease) and are also useful for identifying compds. to prevent and/or treat ACAT-associated disorders.

=> disp l14 ibib abs 1-17
 THE ESTIMATED COST FOR THIS REQUEST IS 48.11 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:n
 REQUEST CANCELED

=> disp l14 ibib 1-17
 THE ESTIMATED COST FOR THIS REQUEST IS 20.06 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L14 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:698235 CAPLUS
 DOCUMENT NUMBER: 143:186773
 TITLE: Methods and compositions relating to modulating
 amyloid precursor protein cleavage
 INVENTOR(S) : Puglielli, Luigi; Huttunen, Henri J.; Guenette,
 Suzanne Y.; Tanzi, Rudolph E.; Kovacs, Dora
 M.
 PATENT ASSIGNEE(S) : The General Hospital Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 34 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005170437	A1	20050804	US 2004-984017	20041108
PRIORITY APPLN. INFO.:			US 2003-518355P	P 20031107

L14 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:474782 CAPLUS
 DOCUMENT NUMBER: 143:1339
 TITLE: Methods using acyl-CoA:cholesterol acyltransferase
 (ACAT) inhibitors for treating ACAT-related diseases
 INVENTOR(S) : Kovacs, Dora M.; Puglielli, Luigi; Tanzi, Rudolph

PATENT ASSIGNEE(S): E.; Frosch, Matthew P.
 USA
 SOURCE: U.S. Pat. Appl. Publ., 28 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005118226	A1	20050602	US 2004-983969	20041108
PRIORITY APPLN. INFO.:			US 2003-518492P	P 20031107

L14 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:934243 CAPLUS
 DOCUMENT NUMBER: 141:388738
 TITLE: Methods and compositions for diagnosing, preventing,
 and treating Alzheimer's disease
 INVENTOR(S): Tanzi, Rudolph E.; Tesco, Giuseppina; Koh,
 Young Ho
 PATENT ASSIGNEE(S): The General Hospital Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004219610	A1	20041104	US 2004-801087	20040315
PRIORITY APPLN. INFO.:			US 2003-454828P	P 20030314
			US 2003-479165P	P 20030617

L14 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:293299 CAPLUS
 DOCUMENT NUMBER: 140:320042
 TITLE: Single nucleotide polymorphisms and mutations on
 α 2-macroglobulin for diagnosing risk of
 Alzheimer's Disease and pharmaceutical preparation
 INVENTOR(S): Becker, Kenneth David; Velicelebi, Gonul; Wang, Xin;
 Bertram, Lars; Saunders, Aleister J.; Tanzi,
 Rudolph E.
 PATENT ASSIGNEE(S): Neurogenetics, Inc., USA; The General Hospital
 Corporation
 SOURCE: U.S. Pat. Appl. Publ., 143 pp., Cont.-in-part of U.S.
 Ser. No. 292,081.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004067512	A1	20040408	US 2003-608397	20030626
US 2003162202	A1	20030828	US 2002-292081	20021108
PRIORITY APPLN. INFO.:			US 2001-337434P	P 20011109
			US 2002-292081	A2 20021108

L14 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:851242 CAPLUS
 DOCUMENT NUMBER: 139:333141

TITLE: Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
 INVENTOR(S): Bush, Ashley I.; Huang, Xudong; Atwood, Craig S.; Tanzi, Rudolph E.
 PATENT ASSIGNEE(S): The General Hospital Corporation, USA
 SOURCE: U.S., 48 pp., Cont.-in-part of U.S. Ser. No. 380,704.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6638711	B1	20031028	US 2000-560883	20000428
WO 9840071	A1	19980917	WO 1998-US4683	19980311
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2005112543	A1	20050526	US 2003-643226	20030819
PRIORITY APPLN. INFO.:				
			US 1997-816122	A 19970311
			WO 1998-US4683	W 19980311
			US 1999-131579P	P 19990429
			US 1999-380704	A2 19990908
			US 2000-560883	A3 20000428
			US 2000-380704	A2 20000606
REFERENCE COUNT:	208	THERE ARE 208 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L14 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:717615 CAPLUS
 DOCUMENT NUMBER: 139:225463
 TITLE: Microsatellite markers on human chromosome 10 associated with Alzheimer's disease and their use in risk assessment, diagnosis and treatment
 INVENTOR(S): Tanzi, Rudolph E.; Becker, Kenneth David; Velicelebi, Gonul; Elliott, Kathryn J.; Wang, Xin; Bertram, Lars; Saunders, Aleister J.; Blacker, Deborah Lynne
 PATENT ASSIGNEE(S): Neurogenetics, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 117 pp., which
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003170678	A1	20030911	US 2002-281456	20021025
PRIORITY APPLN. INFO.:				
			US 2001-348065P	P 20011025
			US 2001-336983P	P 20011102

L14 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:511455 CAPLUS
 DOCUMENT NUMBER: 139:64455

TITLE: Genes and polymorphisms on human chromosome 10
 associated with Alzheimer's disease and other
 neurodegenerative diseases
 INVENTOR(S): Becker, Kenneth David; Velicelebi, Gonul; Elliott,
 Kathryn J.; Wang, Xin; Tanzi, Rudolph E.;
 Bertram, Lars; Saunders, Aleister J.; Mullin, Kristina
 M.; Sampson, Andrew Joseph; Blacker, Deborah Lynne
 PATENT ASSIGNEE(S): Neurogenetics, Inc., USA; The General Hospital
 Corporation
 SOURCE: PCT Int. Appl., 848 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003054143	A2	20030703	WO 2002-US34679	20021025
WO 2003054143	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002364945	A1	20030709	AU 2002-364945	20021025
US 2005009031	A1	20050113	US 2003-600009	20030618
PRIORITY APPLN. INFO.:			US 2001-339525P	P 20011025
			US 2001-336929P	P 20011108
			US 2001-338010P	P 20011108
			US 2001-338363P	P 20011109
			US 2001-337052P	P 20011204
			US 2002-368919P	P 20020328
			US 2002-282174	A2 20021025
			WO 2002-US34679	W 20021025

L14 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:490967 CAPLUS
 DOCUMENT NUMBER: 139:48260
 TITLE: Single nucleotide polymorphisms and mutations on human
 alpha-2-macroglobulin gene which are risk factors for
 Alzheimer's Disease
 INVENTOR(S): Becker, Kenneth David; Velicelebi, Gonul; Wang, Xin;
 Tanzi, Rudolph E.; Bertram, Lars; Saunders,
 Aleister J.
 PATENT ASSIGNEE(S): Neurogenetics, Inc., USA; The General Hospital
 Corporation
 SOURCE: PCT Int. Appl., 178 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051174	A2	20030626	WO 2002-US36095	20021108
WO 2003051174	A3	20040617		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002364894 A1 20030630 AU 2002-364894 20021108

PRIORITY APPLN. INFO.: US 2001-337434P P 20011109
WO 2002-US36095 W 20021108

L14 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:830197 CAPLUS

DOCUMENT NUMBER: 137:336301

TITLE: Therapeutic agents and methods for screening drugs for
Alzheimer's Disease and their effect on
 α -2-macroglobulin (A2M) function and expression

INVENTOR(S): Tanzi, Rudolph E.; Kovacs, Dora; Saunders,
Aleister J.

PATENT ASSIGNEE(S): The General Hospital Corporation, USA

SOURCE: U.S., 47 pp., Cont.-in-part of U.S. 6,342,350.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6472140	B1	20021029	US 1999-241606	19990202
US 6342350	B1	20020129	US 1998-148503	19980904
WO 2000046246	A1	20000810	WO 2000-US2412	20000202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1153036	A1	20011114	EP 2000-907091	20000202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002541770	T	20021210	JP 2000-597316	20000202
US 2002028462	A1	20020307	US 2001-925313	20010810
US 2002114792	A1	20020822	US 2002-52817	20020123
PRIORITY APPLN. INFO.:			US 1997-57655P	P 19970905
			US 1998-93297P	P 19980717
			US 1998-148503	A2 19980904
			US 1999-241606	A 19990202
			WO 2000-US2412	W 20000202

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:158386 CAPLUS

DOCUMENT NUMBER: 136:178011

TITLE: Use of clioquinol for the therapy of Alzheimer's
disease

INVENTOR(S): Bush, Ashley I.; Tanzi, Rudolph E.; Xilinas,
Mikhail; Cherny, Robert

PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont. of U.S. Ser. No.
 560,887.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002025944	A1	20020228	US 2001-972913	20011010
US 2006074104	A1	20060406	US 2005-99693	20050406
PRIORITY APPLN. INFO.:			US 1998-32777	A 19980306
			US 2000-560887	A1 20000428
			US 1999-224953	B1 19990104
			US 2001-972913	A1 20011010

L14 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:553599 CAPLUS
 DOCUMENT NUMBER: 133:159917
 TITLE: Alpha-2-macroglobulin therapies and drug screening
 methods for Alzheimer's disease
 INVENTOR(S): Tanzi, Rudolph E.; Kovacs, Dora M.;
 Saunders, Aleister J.
 PATENT ASSIGNEE(S): General Hospital Corporation, USA
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046246	A1	20000810	WO 2000-US2412	20000202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6472140	B1	20021029	US 1999-241606	19990202
EP 1153036	A1	20011114	EP 2000-907091	20000202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002541770	T	20021210	JP 2000-597316	20000202
PRIORITY APPLN. INFO.:			US 1999-241606	A 19990202
			US 1997-57655P	P 19970905
			US 1998-93297P	P 19980717
			US 1998-148503	A2 19980904
			WO 2000-US2412	W 20000202
REFERENCE COUNT:	13	THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L14 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:594906 CAPLUS
 DOCUMENT NUMBER: 131:209140
 TITLE: Agents for use in the treatment of Alzheimer's disease
 INVENTOR(S): Bush, Ashley L.; Huang, Xudong; Atwood, Craig S.;
 Tanzi, Rudolph E.

PATENT ASSIGNEE(S): The General Hospital Corporation, USA
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945907	A2	19990916	WO 1999-US5291	19990311
WO 9945907	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6323218	B1	20011127	US 1998-38154	19980311
CA 2323458	A1	19990916	CA 1999-2323458	19990311
AU 9929981	A	19990927	AU 1999-29981	19990311
AU 752236	B2	20020912		
EP 1061923	A2	20001227	EP 1999-911307	19990311
EP 1061923	B1	20050615		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506020	T	20020226	JP 2000-535322	19990311
AT 297731	T	20050715	AT 1999-911307	19990311
HK 1033907	A1	20051111	HK 2001-104461	20010627
US 2002082273	A1	20020627	US 2001-956980	20010921
AU 2002318888	A1	20030410	AU 2002-318888	20021213
PRIORITY APPLN. INFO.:				
			US 1998-38154	A 19980311
			AU 1999-29981	A3 19990311
			WO 1999-US5291	W 19990311

L14 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:189240 CAPLUS
 DOCUMENT NUMBER: 130:221671
 TITLE: Polymorphisms at the α 2-macroglobulin gene as
markers of Alzheimer's disease
 INVENTOR(S): Tanzi, Rudolph E.; Hyman, Bradley T.;
Rebeck, George W.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911824	A1	19990311	WO 1998-US18535	19980908
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6342350	B1	20020129	US 1998-148503	19980904

CA 2302829	A1	19990311	CA 1998-2302829	19980908
AU 9892227	A	19990322	AU 1998-92227	19980908
EP 1012341	A1	20000628	EP 1998-944768	19980908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514861	T	20010918	JP 2000-508829	19980908
US 2002028462	A1	20020307	US 2001-925313	20010810
PRIORITY APPLN. INFO.:				
			US 1997-57655P	P 19970905
			US 1998-93297P	P 19980717
			US 1998-148503	A 19980904
			WO 1998-US18535	W 19980908

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:259839 CAPLUS
 DOCUMENT NUMBER: 126:237030
 TITLE: Mutations in S182 gene associated with familial Alzheimer's disease
 INVENTOR(S): Tanzi, Rudolph E.; Wasco, Wilma
 PATENT ASSIGNEE(S): General Hospital Corporation, USA
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708319	A1	19970306	WO 1996-US14114	19960903
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6248555	B1	20010619	US 1996-706344	19960830
CA 2230654	A1	19970306	CA 1996-2230654	19960903
EP 851921	A1	19980708	EP 1996-929872	19960903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11512929	T	19991109	JP 1996-510638	19960903
US 2001012626	A1	20010809	US 2001-785474	20010220
PRIORITY APPLN. INFO.:				
			US 1995-3054P	P 19950831
			US 1996-706344	A 19960830
			WO 1996-US14114	W 19960903

L14 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:205230 CAPLUS
 DOCUMENT NUMBER: 126:195262
 TITLE: Modulators of expression and function of LDL receptor-related protein (LRP), inhibition of amyloid β -precursor protein catabolism, and treatment and diagnosis of Alzheimer's disease
 INVENTOR(S): Strickland, Dudley K.; Hyman, Bradley T.; Kounnas, Maria Z.; Moir, Robert D.; Tanzi, Rudolph E.
 PATENT ASSIGNEE(S): American National Red Cross, USA; General Hospital Corporation
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9704794	A1	19970213	WO 1996-US12686	19960729
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6156311	A	20001205	US 1996-687668	19960726
CA 2246561	A1	19970213	CA 1996-2246561	19960729
US 6447775	B1	20020910	US 1999-441063	19991116
PRIORITY APPLN. INFO.:			US 1995-1600P	P 19950727
			US 1995-1653P	P 19950728
			US 1996-687668	A1 19960726

L14 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:204195 CAPLUS
 DOCUMENT NUMBER: 126:196117
 TITLE: Human chromosome 1 gene STM2/AD4 and gene products related to Alzheimer's disease
 INVENTOR(S): Levy-Lahad, Ephrat; Tanzi, Rudolph E.; Schellenberg, Gerard D.; Wasco, Wilma; Bird, Thomas D.; Mulligan, John; Galas, David J.
 PATENT ASSIGNEE(S): Darwin Molecular Corporation, USA; Va Medical Center; General Hospital Corporation
 SOURCE: PCT Int. Appl., 82 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9703192	A2	19970130	WO 1996-US11386	19960705
WO 9703192	A3	19970403		
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2226255	A1	19970130	CA 1996-2226255	19960705
EP 846171	A2	19980610	EP 1996-926062	19960705
EP 846171	B1	20050921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001517922	T	20011009	JP 1997-505925	19960705
AT 305039	T	20051015	AT 1996-926062	19960705
EP 1637600	A1	20060322	EP 2005-15005	19960705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6468791	B1	20021022	US 1999-375318	19990816
US 2003180880	A1	20030925	US 2002-180781	20020624
PRIORITY APPLN. INFO.:			US 1995-956P	P 19950707
			US 1995-1675P	P 19950728
			US 1995-2174P	P 19950811
			US 1995-2328P	P 19950814
			EP 1996-926062	A3 19960705
			US 1996-675876	B1 19960705
			WO 1996-US11386	W 19960705
			US 1999-375318	A1 19990816

L14 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:397325 CAPLUS
 DOCUMENT NUMBER: 125:53039
 TITLE: A diagnostic assay for Alzheimer's disease: assessment of a beta abnormalities
 INVENTOR(S): Tanzi, Rudolph E.; Bush, Ashley I.; Moir, Robert D.
 PATENT ASSIGNEE(S): General Hospital Corporation, USA
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9612544	A1	19960502	WO 1994-US11895	19941019
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2203142	A1	19960502	CA 1994-2203142	19941019
CA 2203142	C	20060131		
AU 9480830	A	19960515	AU 1994-80830	19941019
US 5972634	A	19991026	US 1997-817423	19970804
US 2003073074	A1	20030417	US 1999-425956	19991025
US 6890727	B2	20050510		
PRIORITY APPLN. INFO.:			WO 1994-US11895	A 19941019
			US 1997-817423	A1 19970804

=>